ABIVAX

Summary

Abivax SA is a French clinical-stage, publicly traded biotechnology company harnessing the immune system to develop novel treatments against inflammatory diseases, viral diseases and cancer.

Deals Overview

Total Deals1

Valued Deals1

Total Value£ 118 M

Avg. Deal Size£ 118 M

Market Context

Senior Management

Marc de Garidel
CEO
Didier Blondel
CFO